These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 11159700)

  • 21. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
    Goren T; Adar L; Sasson N; Weiss YM
    J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
    Finberg JP; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim MB
    Br J Pharmacol; 2006 Nov; 149(6):647-56. PubMed ID: 17016505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
    Hubálek F; Binda C; Li M; Herzig Y; Sterling J; Youdim MB; Mattevi A; Edmondson DE
    J Med Chem; 2004 Mar; 47(7):1760-6. PubMed ID: 15027867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective inhibitors of monoamine oxidase type B and the "cheese effect".
    Finberg JP; Gillman K
    Int Rev Neurobiol; 2011; 100():169-90. PubMed ID: 21971008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
    Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
    Chen JJ; Ly AV
    Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver.
    Ozaita A; Olmos G; Boronat MA; Lizcano JM; Unzeta M; García-Sevilla JA
    Br J Pharmacol; 1997 Jul; 121(5):901-12. PubMed ID: 9222546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
    J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
    Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
    Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
    J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
    Meiring L; Petzer JP; Legoabe LJ; Petzer A
    Bioorg Med Chem Lett; 2022 Jul; 67():128746. PubMed ID: 35447344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
    Finberg JP; Youdim MB
    Neuropharmacology; 2002 Dec; 43(7):1110-8. PubMed ID: 12504917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat.
    Dimpfel W; Hoffmann JA
    Neuropsychobiology; 2010; 62(4):213-20. PubMed ID: 20714170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different sensitivity of mitochondrial and cytosolic monoamine oxidases to in vivo but not in vitro inhibition by specific irreversible inhibitors.
    Moskvitina TA; Medvedev AE
    Med Sci Monit; 2001; 7(1):17-9. PubMed ID: 11208486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation.
    Abu-Raya S; Blaugrund E; Trembovler V; Shilderman-Bloch E; Shohami E; Lazarovici P
    J Neurosci Res; 1999 Nov; 58(3):456-63. PubMed ID: 10518120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor.
    Matsumoto J; Takahashi T; Agata M; Toyofuku H; Sasada N
    Jpn J Pharmacol; 1994 May; 65(1):51-7. PubMed ID: 8089930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
    Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2012 Apr; 119(4):405-14. PubMed ID: 22065207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.